Crescent Biopharma closed at $13.82 on Nov 4, up 5.82%, 48.8% below its 52-week closing high. Volume of 172.9K shares was 0.60× its 20-day average (below normal).
Split-adjusted performance: +1.8% over one month, -23.5% over six months, +11.9% over one year.
Short interest was 4.4M shares at the Oct 15 settlement, down 7.5% from the prior report (21.2% of float, 12.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CBIOCrescent Biopharma | $13.82 | +5.82% | −23.5% | — | — | — | $513.4M | |
| CTMXCytomX Therapeutics | $2.35 | +7.80% | −43.1% | −92.4% | −1457.4% | — | $512.1M | Compare |
| FTHFaeth Therapeutics | $19.99 | +1.73% | — | — | — | — | $516.6M | Compare |
| STTKShattuck Labs | $5.15 | −5.85% | −22.9% | — | — | — | $516.9M | Compare |
| CAPRCapricor Therapeutics | $8.92 | +8.25% | −74.1% | — | — | — | $518.6M | Compare |
| EOLSEvolus | $7.47 | +1.36% | +18.2% | +21.2% | −9.6% | — | $493.4M | Compare |
| OVIDOvid Therapeutics | $2.74 | +14.17% | −1.4% | −88.3% | −2047.6% | — | $535.1M | Compare |
| CLYMClimb Bio | $9.33 | −4.31% | −23.6% | — | — | — | $535.9M | Compare |
| MNPRMonopar Therapeutics | $72.81 | +4.18% | +14.0% | — | — | — | $488.7M | Compare |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
